Tag: Parkinson’s disease
Medtronic receives “landmark” US FDA approval for asleep deep brain stimulation...
Medtronic has received US Food and Drug Administration (FDA) approval of asleep deep brain stimulation (DBS) surgery for people with Parkinson’s disease and people...
AiM partners with Brigham and Women’s Hospital to validate DBS lead...
AiM Medical Robotics has announced a collaboration with Brigham and Women's Hospital (BWH; Boston, USA), and the Surgical Navigation and Robotics (SNR) Lab at Harvard, to validate its cutting-edge robot...
Study elucidates how patient age and electrode connectivity impact cognitive effects...
A study presented at the recent American Academy of Neurology (AAN) annual meeting (13–18 April, Denver, USA) has gone some way to elucidating how...
Insightec launches next-generation Exablate Prime neurosurgery platform in Europe
Insightec has announced the CE-mark approval and European launch of Exablate Prime, which the company describes as a “significant enhancement” to its Exablate Neuro...
Researchers detail “more elegant” DBS approach for improving Parkinson’s symptoms
A team of physicians, neuroscientists and engineers at Duke University (Durham, USA) have reported multiple new strategies that use deep brain stimulation (DBS) to...
Surgical Information Sciences initiates VISION study to support DBS for Parkinson’s...
Surgical Information Sciences (SIS) has announced the commencement of its post-market VISION study evaluating visualisation of the subthalamic nucleus (STN) and globus pallidus internus...
Michael J Fox Foundation announces “significant breakthrough” in search for Parkinson’s...
A “landmark” paper published in The Lancet Neurology by leaders of the Parkinson's Progression Markers Initiative (PPMI)—a study sponsored by The Michael J Fox Foundation (MJFF)...
New spectroscopy probe could enhance deep brain stimulation procedures for Parkinson’s
A new probe that performs two types of spectroscopy could make deep brain stimulation (DBS) procedures safer and improve success rates by helping doctors...
Proof-of-concept study indicates utility of evoked-interference DBS in Parkinson’s disease
Closed-loop evoked-interference deep brain stimulation (DBS) has been shown to be potentially utilisable in characterising the role of oscillatory dynamics in Parkinson’s disease and...
Aleva Neurotherapeutics gains European MRI approval for deep brain stimulation system
Aleva Neurotherapeutics has announced CE-mark approval of its magnetic resonance imaging (MRI) labelling for the directSTIM deep brain stimulation (DBS) system, allowing the technology...
Insightec announces financing up to US$200 million to support continued growth
Insightec has announced that it has signed a credit facility for up to US$200 million with affiliates of existing shareholders, Perceptive Advisors and Community Fund....
Randomised data support use of tDCS in Parkinson’s patients with Pisa...
Data from a randomised controlled trial (RCT), which have been published in Frontiers in Neurology, support the use of neuromodulation with transcranial direct current...
Intranasal delivery of microrobots could trigger new possibilities in treating neurological...
A research team in South Korea has developed and successfully implanted a microrobot device into the brain tissue of mice through the intranasal pathway,...
Insightec announces FDA approval of Exablate Neuro device to treat Parkinson’s...
Insightec has announced that the US Food and Drug Administration (FDA) has approved the Exablate Neuro device for treating advanced Parkinson's disease patients suffering from...
Indian health ministry approves Exablate Neuro focused ultrasound platform
Insightec has announced its incisionless neurosurgery platform, the Exablate 4000, has received market approval by the Central Drugs Standard Control Organization (CDSCO)—part of the Ministry...
Revolution in neurotherapy? Spotlight on focused ultrasound at 2021 EAN congress
While focused ultrasound is by no means a brand-new innovation in the field of neurotherapy—having first been deployed in the 1950s, if not earlier,...
Long-term effectiveness of STN-DBS for Parkinson’s confirmed with 15-year follow-up study
New findings published in Neurology, the medical journal of the American Academy of Neurology (AAN), have confirmed the long-term effectiveness of deep brain stimulation...
Insightec announces approval of Exablate Neuro focused ultrasound platform in Singapore
Insightec has announced approval of its Exablate Neuro platform by the Health Sciences Authority (HSA) in Singapore. The Exablate Neuro (Exablate 4000) platform uses...
Benefits found in directional DBS compared to omnidirectional stimulation for Parkinson’s...
Directional deep brain stimulation (DBS) has demonstrated benefits over omnidirectional DBS for the treatment of Parkinson’s disease in the largest prospective study in this...
New algorithm could enable next-generation deep brain stimulation devices
By delivering small electrical pulses directly to the brain, deep brain stimulation (DBS) can ease tremors associated with Parkinson's disease or help relieve chronic...
Medtronic launches aDBS trial in Parkinson’s disease patients
Medtronic has announced the first enrolment in its trial evaluating the safety and efficacy of adaptive deep brain stimulation (aDBS) in patients with Parkinson’s...
FDA approves Abbott’s iOS-compatible app for the management of chronic pain...
Abbott announces it has received approval from the US Food and Drug Administration (FDA) for the use of its Patient Controller app on compatible...
Boston Scientific announces CE mark approval of the VERCISE Neural Navigator...
Boston Scientific has announced the CE mark approval of the Vercise Neural Navigator 3 directional deep brain stimulation (DBS) programming software—the first system that...
EVER Pharma launches patient friendly subcutaneous pump for Parkinson’s disease
EVER Pharma, a company specialising in neurological diseases, announces the launch of its D-mine Pump. This portable micro infusion device recently received European CE...
Abbott receives CE mark of MR-conditional labelling for Infinity deep brain...
Parkinson’s disease, dystonia and essential tremor patients in CE Mark countries will now benefit from upgraded functionality and new magnetic resonance (MR) conditional labelling...
Boston Scientific launches Vercise primary cell and Vercise Gevia deep brain...
The launch of the Vercise primary cell (PC) and Vercise Gevia deep brain stimulation (DBS) systems, featuring the Vercise Cartesia Directional Lead (Boston Scientific)...
FDA approval of Exablate Neuro for the treatment of tremor-dominant Parkinson’s...
InSightec has announced that The Center for Devices and Radiological Health (CDRH) of the US Food and Drug Administration (FDA) has approved an expansion...
Deep brain stimulation associated with a decreased risk of fall in...
Chronic subthalamic deep brain stimulation (DBS) is associated with a decreased risk for recurrent falls and delays the onset of psychosis in patients with...
Vercise deep brain stimulation system gains FDA approval
The US Food and Drug Administration (FDA) has approved the Vercise deep brain stimulation (DBS) system (Boston Scientific). DBS is used to treat the symptoms...
FDA approves pivotal study of Exablate Neuro for treatment of Parkinson’s...
INSIGHTEC has received approval from the US Food and Drug Administration (FDA) to initiate a pivotal study of the Exablate Neuro for treating dyskinesia...
Aleva Neurotherapeutics raises US$13 million in latest financing round
Aleva Neurotherapeutics has raised US$13 million in a Series D financing round. The round was led by Forrestal Capital, a fund with specific experience...
XADAGO (safinamide) now available in the USA for Parkinson’s disease patients
XADAGO (safinamide) is now available as an add-on therapy for US patients with Parkinson’s disease currently taking levodopa/carbidopa and experiencing “off” episodes. It is not...
Transcranial stimulation and/or physical therapy improves walking speed in Parkinson’s disease
Non-invasive brain stimulation and physical therapy—alone or in combination—improve some measures of walking ability in patients with Parkinson’s disease, concludes a clinical trial in...
Parkinson’s disease patients first to be treated with Leksell Vantage Stereotactic...
The Leksell Vantage Stereotactic system (Elekta) is now in clinical use at three European centres. The first surgeries were performed on a patient with...
CE mark for Vercise Gevia deep brain stimulation system
CE mark has been granted for the Vercise Gevia deep brain stimulation (DBS) system (Boston Scientific), a rechargeable, magnetic resonance (MR) conditional device indicated...
SureTune3 deep brain stimulation software receives Health Canada licence
Medtronic has received a Health Canada licence for SureTune3 software for deep brain stimulation (DBS). The latest innovations in the SureTune technology are designed...
First patient enrolled in APPRISE clinical study for optimisation of Parkinson’s...
Global Kinetics Corporation (GKC) and the Parkinson’s Foundation have announced that the first of over 400 patients has been enrolled in the GKC APPRISE...
Blood test may help differentiate Parkinson’s from atypical Parkinsonism disorders
A blood test may be as accurate as a spinal fluid test when trying to determine whether symptoms are caused by Parkinson’s disease or...
Spinal cord stimulation leads to “significant improvement” in gait in Parkinson’s...
A recent study explores the safety and efficacy of spinal cord stimulation on gait disturbance in advanced Parkinson’s disease. The investigators found that spinal...
Infinity deep brain stimulation system approved in the USA
St Jude Medical has announced the United States Food and Drug Administration approval and first implant of the Infinity deep brain stimulation (DBS) system...
Study finds deep brain stimulation a cost-effective treatment method for Parkinson’s...
It has been established that deep brain stimulation is clinically superior to medical therapy for treating advanced Parkinson’s disease. Jan B Pietzsch (Department of...
